Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Feb;30(2):455-464.
doi: 10.1007/s11136-020-02632-0. Epub 2020 Sep 17.

Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study

Janet H Ford  1 , Virginia L Stauffer  2 , Peter McAllister  3 , Sreelatha Akkala  4 , Matthew Sexson  2 , David W Ayer  2 , Shufang Wang  2
Affiliations
Clinical Trial

Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study

Janet H Ford et al. Qual Life Res. 2021 Feb.

Erratum in

Abstract

Purpose: Migraine can negatively impact patient functioning and quality of life. Here, we report the effects of galcanezumab (GMB), a humanized monoclonal antibody that binds to calcitonin gene-related peptide, on patient-reported outcome (PRO) measures in migraine.

Methods: CGAJ was a Phase III, randomized, open-label study (12-month open-label and 4-month post-treatment follow-up) in patients with episodic or chronic migraine. Patients aged 18-65 years with diagnosis of migraine (≥ 4 migraine headache days per month) as defined by International Classification of Headache Disorders (ICHD)-3 beta guidelines were included in the study. Patients were randomized 1:1 with subcutaneous GMB 120 mg (with a loading dose of 240 mg) or GMB 240 mg given once monthly for 12 months. Changes from baseline in PRO measures such as Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) and Migraine Disability Assessment (MIDAS) were assessed.

Results: A total of 135 patients were randomized to each galcanezumab dose group. Mean (SD) baseline MSQ total scores were 53.85 (20.34) [GMB 120 mg] and 53.69 (18.79) [GMB 240 mg]. For MIDAS, mean (SD) total scores were 45.77 (42.06) [GMB 120 mg] and 53.96 (61.24) [GMB 240 mg]. Within-group mean improvement from baseline on MSQ and MIDAS total scores and all individual item/domain scores were statistically significant for both GMB dose groups, at all-time points during the treatment phase (p < 0.001). For MSQ domain scores, greatest improvement was observed in the Role function-restrictive (RF-R) domain (overall least squares (LS) mean change ± SE: 31.55 ± 1.20 [GMB 120 mg] and 33.40 ± 1.16 [GMB 240 mg]). For MIDAS, the overall LS mean change ± SE from baseline across the entire 12-month treatment phase in total scores were: -33.58 ± 2.11 (GMB 120 mg) and -32.67 ± 2.04 (GMB 240 mg).

Conclusion: Galcanezumab was associated with statistically significant changes from baseline in the PRO measures across the entire 12-month treatment period. These results indicate improved health-related quality of life and decreased disability among patients treated with galcanezumab.

Keywords: Galcanezumab; Migraine; Migraine disability assessment; Migraine-specific quality of life; Open-label study; Patient reported outcomes.

PubMed Disclaimer

Conflict of interest statement

Janet Ford, Virginia Stauffer, Matthew Sexson, David Ayer, Shufang Wang are employees of Eli Lilly and Company, Indianapolis, IN, USA and hold company stock. Peter McAllister is an employee of New England Institute for Neurology and Headache, USA. He is an independent contractor and part of speaker bureaus at Teva Pharmaceuticals, Amgen and Allergan. Sreelatha Akkala is a full-time employee of Eli Lilly Services India Pvt. Ltd, India.

Figures

Fig. 1
Fig. 1
Least squares (LS) mean change from baseline ± standard error for Migraine-specific Quality of Life domains and Total scores during treatment and post-treatment phase
Fig. 2
Fig. 2
Least squares (LS) mean change from baseline ± standard error for MIDAS total score during treatment and post-treatment phase and MIDAS items during treatment phase
Fig. 3
Fig. 3
Mean changes from baseline in monthly migraine headache days during treatment and post-treatment phase
See this image and copyright information in PMC

References

    1. Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013;53(2):230–246. doi: 10.1111/head.12038. - DOI - PubMed
    1. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. Journal of the Neurological Sciences. 2017;372:307–315. doi: 10.1016/j.jns.2016.11.071. - DOI - PubMed
    1. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
    1. Headache Classification Committee of the International Headache, S The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. - PubMed
    1. Ruiz de la Torre E, Martelletti P, Craven A, Walsh D, Evans S, Dumas P, et al. Real-world patient perspective on the burden and impact of migraine. Cephalalgia. 2017;37:319–374. doi: 10.1177/0333102417732504. - DOI - PubMed

Publication types

Substances